Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Debt (2016 - 2025)

China Pharma Holdings' Total Debt history spans 16 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Total Debt fell 22.04% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 22.04%, while the annual FY2025 figure was $2.0 million, 22.04% down from the prior year.
  • Total Debt reached $2.0 million in Q4 2025 per CPHI's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $5.1 million in Q3 2021 to a low of $2.0 million in Q3 2025.
  • Average Total Debt over 5 years is $3.0 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Total Debt: soared 91.76% in 2021, then plummeted 47.58% in 2023.
  • A 5-year view of Total Debt shows it stood at $4.3 million in 2021, then plummeted by 43.61% to $2.4 million in 2022, then grew by 0.07% to $2.4 million in 2023, then rose by 3.83% to $2.5 million in 2024, then fell by 22.04% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Total Debt are $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.7 million (Q2 2025).